Placebo Unblinding Process For Pfizer’s COVID Vaccine No Detriment To US FDA Safety Analysis

Despite initial concerns among FDA staff and its advisory committee about unblinding the Comirnaty pivotal trial after emergency authorization, agency’s review of the first COVID vaccine to receive full licensure suggests its safety conclusions were not adversely affected.

Drug Review Profile: Comirnaty
When Pfizer/BioNTech opened the door to placebo recipients to get vaccinated, the FDA worried about how interpretation of the study results would be impacted.

More from Drug Review Profiles

More from Product Reviews